Clinical Trials Logo

Healthy Volunteers clinical trials

View clinical trials related to Healthy Volunteers.

Filter by:

NCT ID: NCT06329895 Not yet recruiting - Healthy Volunteers Clinical Trials

A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants

Start date: March 25, 2024
Phase: Phase 1
Study type: Interventional

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC refers to a type of lung cancer that has spread from the lungs to nearby tissues or other body parts. People with advanced NSCLC may have changes in certain proteins, like EGFR and HER2, that cause uncontrolled cell growth and increased spread of cancer. In this study, participants will be healthy and will not benefit from taking the study treatment, BAY2927088. However, the study will provide information about how to test BAY2927088 in future studies with people who have advanced NSCLC with EGFR or HER2 mutations. BAY2927088 is under development for the treatment of advanced NSCLC with EGFR or HER2 mutations. It is expected to work against these changed proteins, which might slow down the spread of cancer. Researchers think that BAY2927088 inhibits drug transporters such as P-gp (P-glycoprotein) and breast cancer resistance protein (BCRP). Drug transporters are proteins that help in the movement of certain drugs into, through, and out of the body's cells. Dabigatran is a drug used in the treatment of blood clots in a vein and rosuvastatin is a drug used in the treatment of high cholesterol in the blood. The main purpose of this study is to find out how BAY2927088, taken as multiple doses, affects the levels of dabigatran and rosuvastatin in the blood of healthy participants. For this, researchers will measure the following for dabigatran and rosuvastatin, when given with and without BAY2927088: - Area under the curve (AUC): a measure of the total amount of the drug in participants' blood over time - Maximum observed concentration (Cmax): the highest amount of the drug in participants' blood In this study, participants will take the following treatments: - Dabigatran in the morning of Day 1 and 9. - Rosuvastatin in the morning of Day 3 and 12. - BAY2927088 two times a day in the morning and evening of Days 6 to 15. Participants will be in this study for about 8 weeks with 3 visits to the study clinic. Participants will visit the study clinic: - at least once, 2 to 28 days before the treatment starts, to confirm they can take part in this study - once on the day before the treatment starts and will stay in the clinic until Day 16 of the treatment - once, 7 to 10 days after last dose of BAY2927088, for a health check-up During the study, the doctors and their study team will: - do physical examinations - collect blood samples from the participants to measure the levels of dabigatran, rosuvastatin and of BAY2927088 - check participants' health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram (ECG) - ask the participants questions about how they are feeling and what adverse events they are having An adverse event is any medical problem that a participant has during a study. The study doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.

NCT ID: NCT06329609 Not yet recruiting - Healthy Volunteers Clinical Trials

Airvo 3 Respiratory Rate Validation Study

Start date: April 2024
Phase: N/A
Study type: Interventional

This is a clinical performance testing to validate the accuracy of the Airvo 3 device with respiratory rate algorithm manufactured by Fisher & Paykel Healthcare for continuous respiratory rate monitoring.

NCT ID: NCT06326723 Completed - Healthy Volunteer Clinical Trials

Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects

Start date: September 4, 2023
Phase: Phase 1
Study type: Interventional

This clinical study is a single-center, randomized, double-blind, placebo-controlled Phase 1 clinical study to assess the PK characteristics and safety and tolerability of single and multiple dose daridorexant in 32 healthy adult Chinese subjects.

NCT ID: NCT06326606 Recruiting - Healthy Volunteers Clinical Trials

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants

Start date: March 2024
Phase: Phase 1
Study type: Interventional

MLS101 is being developed as a low dose psilocybin, that can be administered to treat various neurological and psychiatric conditions. The purpose of this clinical trial is to assess how safe and tolerated MLS101 is; to see how MLS101 is distributed and cleared by the body (pharmacokinetics); and to assess the psychedelic effects of MLS101 in healthy adult participants.

NCT ID: NCT06324604 Not yet recruiting - Healthy Volunteers Clinical Trials

Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients

Start date: June 2024
Phase: Phase 1
Study type: Interventional

First in human study to understand the potential side effects of MTX-101, how long MTX-101 lasts in the human body, and how MTX-101 affects specific human immune cells.

NCT ID: NCT06323655 Completed - Healthy Volunteers Clinical Trials

Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects

Start date: July 19, 2018
Phase: Phase 1
Study type: Interventional

The aim of this study is to investigate next-day residual effects of tasimelteon compared with placebo and active control in healthy subjects.

NCT ID: NCT06320574 Not yet recruiting - Healthy Volunteers Clinical Trials

Nurses' Competence in Gastric Ultrasound

SKILLS-1
Start date: March 14, 2024
Phase:
Study type: Observational

The goal of this observational cohort study is to investigate gastric ultrasound skills in surgical nurses. The main question it aims to answer is: • how much training is required for surgical nurses to obtain competency in performing gastric ultrasound. Participants will follow a training involving - theoretical background using e-learning, picture library and lecture - practical skill development in an interactive hands-on workshop on live models directed by expert gastric ultrasonographer - and formative assessments during training sessions scanning healthy volunteers by participants and examiners (expert gastric ultrasonographers).

NCT ID: NCT06320106 Recruiting - Healthy Volunteers Clinical Trials

Assessment of Navigation Abilities in Children With Cerebral Palsy and Their Peers

Start date: February 7, 2023
Phase: N/A
Study type: Interventional

Spatial navigation skills are very important in everyday activities and quality of life but spatial navigation abilities are not part of the standard process of assessment and rehabilitation of patients. Furthermore, it is known that children with cerebral palsy have impaired visuo-spatial competences. The main objective of this study is to evaluate and compare the spatial navigation abilities of typically developing children and of children with cerebral palsy using the "StarMaze" application delivered by means of a Head Mounted Display (HMD). The second aim is to investigate the user experience during the session. A similar application was already developed and tested in a virtual reality large scale platform whose size and cost limit the accessibility. Therefore, the assessment (and future training) of navigation abilities with affordable and easy-to-use technology such as HMD open new perspectives.

NCT ID: NCT06318845 Active, not recruiting - Healthy Volunteers Clinical Trials

Phase 1 Study to Evaluate the Safety and Pharmacokinetic Drug Interaction of DHP2302R1 and DHP2302R2

Start date: March 4, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the safety and drug interaction of DHP2302R1 and DHP2302R2 when administered alone versus in combination in healthy South Korean adult participants.

NCT ID: NCT06314880 Recruiting - Healthy Volunteers Clinical Trials

Phase I Clinical Trial of Recombinant Meningococcal Group B Vaccine (E. Coli) in a Population Aged 3 Months-50 Years Old

Start date: July 22, 2023
Phase: Phase 1
Study type: Interventional

The research objective is to evaluate the safety and tolerability of the recombinant Group B meningococcal vaccine (E. coli) and explore its preliminary immunogenicity.